Aequus Change To Account Receivables vs Other Non Cash Items Analysis

AQS Stock

CAD 0.01 0.01 50.00%

Aequus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Aequus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aequus Pharmaceuticals is a good investment. Please check the relationship between Aequus Pharmaceuticals Change To Account Receivables and its Other Non Cash Items accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aequus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Change To Account Receivables vs Other Non Cash Items

Change To Account Receivables vs Other Non Cash Items Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aequus Pharmaceuticals Change To Account Receivables account and Other Non Cash Items. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Aequus Pharmaceuticals' Change To Account Receivables and Other Non Cash Items is 0.1. Overlapping area represents the amount of variation of Change To Account Receivables that can explain the historical movement of Other Non Cash Items in the same time period over historical financial statements of Aequus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Aequus Pharmaceuticals' Change To Account Receivables and Other Non Cash Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Account Receivables of Aequus Pharmaceuticals are associated (or correlated) with its Other Non Cash Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Non Cash Items has no effect on the direction of Change To Account Receivables i.e., Aequus Pharmaceuticals' Change To Account Receivables and Other Non Cash Items go up and down completely randomly.

Correlation Coefficient

0.1

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Change To Account Receivables

Other Non Cash Items

Most indicators from Aequus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aequus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aequus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Aequus Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 8.81 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.21) in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	128.1K	129.8K	138.2K	147.6K
Interest Income	13.2K	24.7K	4.1K	3.9K

Reconciled Depreciation Interest Income

Aequus Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Other Current Liab	Non Currrent Assets Other	Other Assets	Intangible Assets	Short Term Investments	Net Invested Capital
Total Assets		0.05	0.51	0.49	-0.01	-0.36	-0.34	0.42	0.84	0.41	0.84	0.68	0.35	0.24	0.56	0.69	0.1	0.94	0.42	0.19	-0.01	0.29	0.32	-0.19	-0.25	0.42
Total Current Liabilities	0.05		-0.76	0.5	0.77	0.78	-0.73	0.05	-0.12	0.36	-0.11	-0.1	0.69	0.72	0.31	-0.36	0.92	-0.07	0.59	0.48	0.16	-0.48	-0.5	-0.65	-0.55	-0.63
Total Stockholder Equity	0.51	-0.76		0.02	-0.79	-0.94	0.53	0.28	0.6	-0.04	0.58	0.33	-0.49	-0.53	0.01	0.56	-0.8	0.56	-0.38	-0.56	-0.17	0.45	0.46	0.62	0.49	0.84
Net Tangible Assets	0.49	0.5	0.02		0.22	-0.06	-0.28	0.13	0.55	0.07	0.57	0.01	0.35	0.22	0.42	-0.22	0.33	0.51	0.24	-0.07	0.26	-0.3	-0.35	-0.18	-0.14	-0.08
Property Plant And Equipment Net	-0.01	0.77	-0.79	0.22		0.77	-0.84	-0.23	-0.24	0.28	-0.23	0.13	0.8	0.69	0.5	-0.22	0.91	-0.1	0.73	0.82	0.51	-0.34	-0.33	-0.88	-0.78	-0.75
Net Debt	-0.36	0.78	-0.94	-0.06	0.77		-0.67	-0.26	-0.56	0.2	-0.55	-0.08	0.59	0.65	0.08	-0.3	0.85	-0.46	0.54	0.64	-0.01	-0.31	-0.33	-0.67	-0.62	-0.75
Retained Earnings	-0.34	-0.73	0.53	-0.28	-0.84	-0.67		0.05	0.08	-0.6	0.07	-0.51	-0.94	-0.79	-0.7	-0.2	-0.85	-0.16	-0.97	-0.77	-0.28	0.1	0.15	0.79	0.89	0.53
Accounts Payable	0.42	0.05	0.28	0.13	-0.23	-0.26	0.05		0.34	0.55	0.34	-0.12	-0.17	-0.07	0.11	0.17	-0.03	0.25	-0.05	-0.24	-0.22	-0.12	-0.13	0.34	0.28	0.06
Cash	0.84	-0.12	0.6	0.55	-0.24	-0.56	0.08	0.34		-0.09	1.0	0.33	-0.03	-0.1	0.18	0.43	-0.11	0.95	-0.04	-0.03	-0.13	0.25	0.33	0.0	0.08	0.53
Non Current Assets Total	0.41	0.36	-0.04	0.07	0.28	0.2	-0.6	0.55	-0.09		-0.09	0.36	0.49	0.46	0.63	0.35	0.33	0.08	0.64	0.17	0.13	-0.19	-0.27	-0.1	-0.3	-0.18
Cash And Short Term Investments	0.84	-0.11	0.58	0.57	-0.23	-0.55	0.07	0.34	1.0	-0.09		0.33	-0.02	-0.09	0.19	0.42	-0.1	0.95	-0.03	-0.03	-0.13	0.24	0.32	-0.01	0.07	0.52
Net Receivables	0.68	-0.1	0.33	0.01	0.13	-0.08	-0.51	-0.12	0.33	0.36	0.33		0.51	0.37	0.55	0.87	0.08	0.61	0.63	0.44	0.03	0.64	0.62	-0.39	-0.61	0.31
Common Stock Shares Outstanding	0.35	0.69	-0.49	0.35	0.8	0.59	-0.94	-0.17	-0.03	0.49	-0.02	0.51		0.79	0.63	0.15	0.78	0.2	0.96	0.7	0.38	-0.1	-0.13	-0.8	-0.84	-0.42
Inventory	0.24	0.72	-0.53	0.22	0.69	0.65	-0.79	-0.07	-0.1	0.46	-0.09	0.37	0.79		0.46	0.09	0.78	0.1	0.75	0.62	0.22	-0.12	-0.1	-0.76	-0.7	-0.26
Other Current Assets	0.56	0.31	0.01	0.42	0.5	0.08	-0.7	0.11	0.18	0.63	0.19	0.55	0.63	0.46		0.3	0.38	0.39	0.71	0.35	0.54	-0.11	-0.18	-0.36	-0.54	-0.16
Other Stockholder Equity	0.69	-0.36	0.56	-0.22	-0.22	-0.3	-0.2	0.17	0.43	0.35	0.42	0.87	0.15	0.09	0.3		-0.18	0.62	0.34	0.24	-0.31	0.68	0.7	-0.06	-0.26	0.53
Total Liab	0.1	0.92	-0.8	0.33	0.91	0.85	-0.85	-0.03	-0.11	0.33	-0.1	0.08	0.78	0.78	0.38	-0.18		0.0	0.72	0.77	0.18	-0.33	-0.32	-0.84	-0.74	-0.68
Total Current Assets	0.94	-0.07	0.56	0.51	-0.1	-0.46	-0.16	0.25	0.95	0.08	0.95	0.61	0.2	0.1	0.39	0.62	0.0		0.23	0.15	-0.06	0.37	0.44	-0.18	-0.17	0.51
Common Stock	0.42	0.59	-0.38	0.24	0.73	0.54	-0.97	-0.05	-0.04	0.64	-0.03	0.63	0.96	0.75	0.71	0.34	0.72	0.23		0.71	0.28	-0.01	-0.06	-0.71	-0.85	-0.39
Property Plant Equipment	0.19	0.48	-0.56	-0.07	0.82	0.64	-0.77	-0.24	-0.03	0.17	-0.03	0.44	0.7	0.62	0.35	0.24	0.77	0.15	0.71		0.17	0.09	0.17	-0.92	-0.83	-0.46
Other Current Liab	-0.01	0.16	-0.17	0.26	0.51	-0.01	-0.28	-0.22	-0.13	0.13	-0.13	0.03	0.38	0.22	0.54	-0.31	0.18	-0.06	0.28	0.17		-0.29	-0.31	-0.32	-0.25	-0.28
Non Currrent Assets Other	0.29	-0.48	0.45	-0.3	-0.34	-0.31	0.1	-0.12	0.25	-0.19	0.24	0.64	-0.1	-0.12	-0.11	0.68	-0.33	0.37	-0.01	0.09	-0.29		0.97	-0.04	-0.27	0.44
Other Assets	0.32	-0.5	0.46	-0.35	-0.33	-0.33	0.15	-0.13	0.33	-0.27	0.32	0.62	-0.13	-0.1	-0.18	0.7	-0.32	0.44	-0.06	0.17	-0.31	0.97		-0.09	-0.21	0.52
Intangible Assets	-0.19	-0.65	0.62	-0.18	-0.88	-0.67	0.79	0.34	0.0	-0.1	-0.01	-0.39	-0.8	-0.76	-0.36	-0.06	-0.84	-0.18	-0.71	-0.92	-0.32	-0.04	-0.09		0.87	0.46
Short Term Investments	-0.25	-0.55	0.49	-0.14	-0.78	-0.62	0.89	0.28	0.08	-0.3	0.07	-0.61	-0.84	-0.7	-0.54	-0.26	-0.74	-0.17	-0.85	-0.83	-0.25	-0.27	-0.21	0.87		0.47
Net Invested Capital	0.42	-0.63	0.84	-0.08	-0.75	-0.75	0.53	0.06	0.53	-0.18	0.52	0.31	-0.42	-0.26	-0.16	0.53	-0.68	0.51	-0.39	-0.46	-0.28	0.44	0.52	0.46	0.47

Click cells to compare fundamentals

Aequus Pharmaceuticals Account Relationship Matchups

Aequus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.7M	3.1M	4.3M	1.7M	1.1M	1.0M
Total Current Liabilities	476.0K	384.3K	2.5M	2.4M	4.8M	5.0M
Total Stockholder Equity	(877.1K)	574.0K	1.8M	(1.4M)	(4.3M)	(4.1M)
Net Tangible Assets	934.2K	(961.9K)	574.0K	1.8M	1.6M	1.7M
Property Plant And Equipment Net	480.1K	366.3K	242.3K	788.8K	650.6K	683.1K
Net Debt	1.7M	604.7K	(211.3K)	533.1K	4.9M	5.1M
Retained Earnings	(23.7M)	(24.7M)	(26.5M)	(29.7M)	(32.7M)	(31.1M)
Accounts Payable	249.5K	160.9K	157.1K	88.5K	274.2K	286.1K
Cash	484.5K	1.7M	2.4M	249.8K	170.2K	161.7K
Non Current Assets Total	564.9K	366.3K	755.1K	788.8K	650.6K	710.7K
Cash And Short Term Investments	484.5K	1.7M	2.4M	294.7K	215.0K	204.3K
Net Receivables	556.3K	779.5K	941.1K	310.1K	31.7K	30.1K
Common Stock Shares Outstanding	80.4M	93.2M	128.8M	132.6M	152.5M	83.9M
Liabilities And Stockholders Equity	1.7M	3.1M	4.3M	1.7M	1.1M	1.0M
Inventory	5.4K	123.3K	139.8K	93.8K	123.7K	129.9K
Other Current Assets	61.5K	146.7K	120.5K	204.1K	65.1K	113.5K
Other Stockholder Equity	3.7M	4.1M	4.3M	(1.0)	(1.15)	(1.09)
Total Liab	2.5M	2.6M	2.6M	3.1M	5.4M	5.6M
Total Current Assets	1.1M	2.8M	3.6M	902.7K	435.6K	413.8K
Common Stock	18.9M	19.1M	21.2M	24.0M	27.6M	17.2M
Property Plant Equipment	14.1K	480.1K	366.3K	242.3K	278.6K	292.6K
Other Current Liab	83K	76.3K	221.7K	2.2M	42.1K	40.0K
Non Currrent Assets Other	19.0K	761.5K	512.8K	(1.0)	(1.15)	(1.09)
Non Current Liabilities Total	2.1M	2.2M	102.0K	693.8K	583.6K	774.1K
Net Invested Capital	888.3K	2.6M	3.7M	620.0K	76.2K	72.3K
Net Working Capital	631.7K	2.4M	1.1M	(1.5M)	(4.4M)	(4.1M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aequus Stock Analysis

When running Aequus Pharmaceuticals' price analysis, check to measure Aequus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aequus Pharmaceuticals is operating at the current time. Most of Aequus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aequus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aequus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aequus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC